.jpg)
.jpg)
01 Apr, 2020
77.jpg)
Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint
Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..
U.S. Industrial Output Expected to Show Gains
Experts believe that the U.S. Industrial output numbers could give cause for celebration. The numbers are expected to show a gain. Preliminary numbers promise to make good these expectations.As far as industrial activity goes. the numbers have shown..
.jpg)
Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials
Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..
bluebird bio Inc Shares Up After Phase 1 clinical Study Update
Shares of the innovative clinical-stage biotechnology company bluebird bio Inc. (NASDAQ: BLUE) have jumped more than 13% Tuesday, after the company together with their partner Celgene Corporation (NASDAQ: CELG) reported updated results from the ongo..
@Newsletter
Sign Up for Weekly UpdatesOpt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!
No articles found.
.jpg){kind=small}
All rights reserved.
No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).